STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
One study showed that a Novartis drug, pelacarsen, had no effect on the rate of heart attacks and strokes despite lowering a substance in the blood called lp(a), which genetics said should reduce cardiovascular risk.
Key points
- Because again and again, pharmaceutical researchers have learned the same hard lesson: technologies that were supposed to speed new medicines to patients have fallen short.
- Another large study, from Novo Nordisk, of an anti-inflammatory targeting a protein called IL-6 also showed no benefit.
- A new understanding of genetics was supposed to increase the odds of success – and did anything but.
The next time someone tells you that artificial intelligence, or any other new technology, is going to cure every disease, point them to the effort to fight heart attacks and strokes, which together are the largest killer in the developed world.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.